Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical ...

The survival rate for people with lung cancer is improving, according to the new State of Lung Cancer report. The American Lung Association report says there have been important advances in early ...

Survival rates for lung cancer are improving, especially among historically marginalized communities of color, according to a new survey from the American Lung Association released Tuesday. The ...

The study examined 180 patients with advanced lung cancer who received a COVID vaccine within 100 days before or after beginning immunotherapy, as well as 704 similar patients who did not. Vaccinated ...

Over the past five years, the five-year survival rate for lung cancer in the US has increased a significant 22%, according to a new report from the American Lung Association. But the number of people ...

Could the COVID-19 vaccine secretly help fight cancer? A new study from the University of Florida and MD Anderson reveals ...

Rybrevant plus Lazcluze significantly extends overall survival in EGFR-mutated NSCLC compared to Tagrisso, with benefits continuing beyond the follow-up period. The combination therapy improves ...

Lung cancer is hard to catch early and even harder to survive once it is found. A new clinical trial will test whether a ...

Angus Chen covers all issues broadly related to cancer including drugs, policy, science, and equity. He joined STAT in 2021 after covering health and science at NPR and NPR affiliate stations. His ...

In Brazil, the early detection of genetic alterations in lung cancer through liquid biopsies could be a valuable tool for expediting diagnoses and guiding patient treatment.

Patients with rheumatoid arthritis (RA) who receive immune checkpoint inhibitor (ICI) therapy for cancer do not appear to face higher mortality compared against patients without RA receiving the same ...

AstraZeneca said on Monday that a late‑stage trial testing its blockbuster therapy Imfinzi in combination with its ...